Item 1. Legal Proceedings
Item 1. Legal Proceedings.
Securities Class Action
Litigation . On July 26, 2022 and July 28, 2022, securities class action complaints were filed by purported stockholders of ours
in the United States District Court for the Central District of California against us and certain of our current and former officers
and directors. The complaints allege, among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities
Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material
fact in connection with the Company’s relationship with Serhat Gümrükcü and its commercial prospects. The
complaints seek unspecified damages, interest, fees, and costs. The defendants have not yet responded to the complaints.
Federal Derivative Litigation .
On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central
District of California. On January 19, 2023, John Solak filed a substantially similar shareholder derivative action in the United
States District Court for the District of Delaware. Both derivative actions recite similar underlying facts as those alleged in
the Securities Class Action Litigation. The actions, filed on behalf of the Company, name Serhat Gümrükcü and certain
of the Company’s current and former directors as defendants. The actions also name the Company as a nominal defendant. The
actions allege violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and also set out claims for breach
of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiffs do not quantify any
alleged injury, but seek damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United States
District Court for the Central District of California stayed the Koenig matter pending resolution of the defendants’ anticipated
motion to dismiss in the Securities Class Action Litigation. The defendants have not yet responded to either complaint.
State Derivative Litigation .
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County,
reciting similar underlying facts as those alleged in the Securities Class Action Litigation. The action, filed on behalf of the
Company, names Serhat Gümrükcü and certain of the Company’s current and former directors as defendants. The
action also names the Company as a nominal defendant. The action sets out claims for breaches of fiduciary duty, contribution and
indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged injury, but seeks damages,
disgorgement, restitution, and other costs and expenses. The defendants have not yet responded to the complaint.
On October 21, 2022, the
Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat Gümrükcü,
William Anderson Wittekind, G Tech Bio LLC, SG & AW Holdings LLC, and Seraph Research Institute. The Complaint alleges that
the defendants engaged in a “concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results
of multiple studies supporting its [Hepatitis B] and SARS-CoV-2/influenza pipelines.” Specifically, “Defendants manipulated
negative results to reflect positive outcomes from various studies, and even fabricated studies out of whole cloth.” As a
result of the defendants’ conduct, the Company claims that it “paid approximately $25 million to Defendants and third-parties
that it would not otherwise have paid.” The defendants have not yet answered the allegations set forth in the Company’s
Complaint.
On December 28, 2022, the
Company received a demand letter on behalf of Weird Science LLC (“Weird Science”), William Anderson Wittekind, the
William Anderson Wittekind 2020 Annuity Trust, the William Anderson Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity
Trust, and the Ty Mabry 2021 Annuity Trust alleging that the Company breached the February 16, 2018 Investor Rights Agreement between
the Company, Weird Science, and RS Group ApS. Specifically, the demand letter alleges that the Company “breached its obligations
under the Investor Rights Agreement to provide the requisite thirty days’ notice” to Holders of Registrable Securities
in connection with SEC Form S-3 filings on July 13, 2020 and February 11, 2022 and demands over $64 million in damages. The Company
denies these allegations and intends to vigorously defend against this claim.
On March 1, 2021, former
Enochian BioSciences Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District
Court for the District of Vermont against the Company, Enochian BioSciences Denmark ApS, and certain directors and officers. In the
Complaint, Mr. Wolfe and Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that
the Company lacked probable cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages,
as well as punitive damages. The allegations in the Complaint relate to an earlier action filed by the Company and Enochian
BioSciences Denmark ApS in the Vermont Superior Court, Orange Civil Division. On March 3, 2022, the court partially granted the
Company’s motion to dismiss, dismissing the abuse of process claim against all defendants and all claims against Mark Dybul
and Henrik Grønfeldt-Sørensen. On November 29, 2022, the Company filed a motion for summary judgment with respect to the
sole remaining claim of malicious prosecution. The Company denies the allegations set forth in the Complaint and will continue to
vigorously defend against the remaining claim.
35
Item 1A. Risk Factors.
Risk factors that may affect
our business and financial results are discussed within Item 1A ”Risk Factors” of our annual report for the fiscal
year ended June 30, 2022, on Form 10-K (“2022 Form 10-K”) filed with the SEC on February 27, 2023. There
have been no material changes to the disclosures relating to this item from those set forth in our 2022 Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.